These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9708870)

  • 1. P-value interpretation and alpha allocation in clinical trials.
    Moyé LA
    Ann Epidemiol; 1998 Aug; 8(6):351-7. PubMed ID: 9708870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-II error rates (beta errors) of randomized trials in orthopaedic trauma.
    Lochner HV; Bhandari M; Tornetta P
    J Bone Joint Surg Am; 2001 Nov; 83(11):1650-5. PubMed ID: 11701786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha calculus in clinical trials: considerations and commentary for the new millennium.
    Moyé LA
    Stat Med; 2000 Mar; 19(6):767-79. PubMed ID: 10734280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sizing clinical trials with variable endpoint event rates.
    Moyé LA
    Stat Med; 1997 Oct; 16(20):2267-82. PubMed ID: 9351164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping guidelines for clinical trials with multiple treatments.
    Hughes MD
    Stat Med; 1993 May; 12(10):901-15. PubMed ID: 8337547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low power and type II errors in recent ophthalmology research.
    Khan Z; Milko J; Iqbal M; Masri M; Almeida DRP
    Can J Ophthalmol; 2016 Oct; 51(5):368-372. PubMed ID: 27769328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical considerations in the intent-to-treat principle.
    Lachin JM
    Control Clin Trials; 2000 Jun; 21(3):167-89. PubMed ID: 10822117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conducting clinical trials to establish drug efficacy in chronic pain.
    Harden RN; Bruehl S
    Am J Phys Med Rehabil; 2001 Jul; 80(7):547-57. PubMed ID: 11421526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint.
    Borm GF; Houben RM; Welsing PM; Zielhuis GA
    J Clin Epidemiol; 2006 Jan; 59(1):1-6. PubMed ID: 16360554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primer: measuring the effects of treatment in clinical trials.
    Ward MM
    Nat Clin Pract Rheumatol; 2007 May; 3(5):291-7. PubMed ID: 17471248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials and p-values, beware of the extremes.
    Cleophas TJ
    Clin Chem Lab Med; 2004 Mar; 42(3):300-4. PubMed ID: 15080563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A generalized concept of power helped to choose optimal endpoints in clinical trials.
    Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
    J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size allocation to regions in a multiregional trial.
    Uesaka H
    J Biopharm Stat; 2009 Jul; 19(4):580-94. PubMed ID: 20183427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.